ZA9711004B - Method for treating preventing heart failure and ventricular dilatation - Google Patents

Method for treating preventing heart failure and ventricular dilatation

Info

Publication number
ZA9711004B
ZA9711004B ZA9711004A ZA9711004A ZA9711004B ZA 9711004 B ZA9711004 B ZA 9711004B ZA 9711004 A ZA9711004 A ZA 9711004A ZA 9711004 A ZA9711004 A ZA 9711004A ZA 9711004 B ZA9711004 B ZA 9711004B
Authority
ZA
South Africa
Prior art keywords
heart failure
preventing heart
ventricular dilatation
treating preventing
treating
Prior art date
Application number
ZA9711004A
Other languages
English (en)
Inventor
Joseph T Peterson Jr
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA9711004B publication Critical patent/ZA9711004B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • External Artificial Organs (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
ZA9711004A 1996-12-09 1997-12-08 Method for treating preventing heart failure and ventricular dilatation ZA9711004B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3263196P 1996-12-09 1996-12-09

Publications (1)

Publication Number Publication Date
ZA9711004B true ZA9711004B (en) 1998-10-05

Family

ID=21865971

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9711004A ZA9711004B (en) 1996-12-09 1997-12-08 Method for treating preventing heart failure and ventricular dilatation

Country Status (13)

Country Link
US (1) US5948780A (no)
EP (1) EP1028716A1 (no)
JP (1) JP2001526631A (no)
KR (1) KR20000057444A (no)
AU (1) AU741768B2 (no)
BR (1) BR9714385A (no)
CA (1) CA2263886A1 (no)
IL (1) IL128545A0 (no)
MX (1) MXPA99001974A (no)
NO (1) NO992769L (no)
NZ (1) NZ334897A (no)
WO (1) WO1998025597A2 (no)
ZA (1) ZA9711004B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321293A (en) * 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
HU222986B1 (hu) * 1995-12-22 2004-01-28 Warner-Lambert Co. A mátrix metalloproteinázok működését gátló aromás ketosavak és azok származékai
CZ298814B6 (cs) * 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonované deriváty aminokyselin a metaloproteasové inhibitory obsahující tyto deriváty
US6624177B1 (en) * 1996-09-04 2003-09-23 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
WO1999047138A1 (en) * 1998-03-17 1999-09-23 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
DOP2002000333A (es) * 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
ES2231708T3 (es) * 2001-02-14 2005-05-16 Warner-Lambert Company Llc Benzotiadicinas inhibidoras de metaloproteinasa de matriz.
EP1368323B1 (en) * 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
HU230352B1 (hu) * 2001-06-12 2016-02-29 Wellstat Therapeutics Corporation Metabolikus rendellenességek kezelésére adható vegyületek és ezeket tartalmazó gyógyászati készítmények
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
CA2457033A1 (en) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. A medecine for cardiac failure
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
BR0312708A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib
BR0312943A (pt) * 2002-07-17 2005-07-12 Warner Lambert Co Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
MXPA05000722A (es) * 2002-07-17 2005-04-08 Warner Lambert Co Combinacion de un inhibidor alosterico carboxilico de la metaloproteinasa-13 de la matriz con un inhibidor selectivo de la ciclooxigenasa-2 que no es celecoxib o valdecoxib.
CA2491820A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB201312311D0 (en) * 2013-07-09 2013-08-21 Uni I Oslo Uses of enzyme inhibitors
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
WO1995029689A1 (en) * 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
AU717570B2 (en) * 1995-06-02 2000-03-30 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
NZ321293A (en) * 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
CZ298814B6 (cs) * 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonované deriváty aminokyselin a metaloproteasové inhibitory obsahující tyto deriváty
JP2000511175A (ja) * 1996-05-17 2000-08-29 ワーナー―ランバート・コンパニー ビフェニルスルホンアミドマトリックスメタロプロテイナーゼ阻害剤
JP2002514180A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
CA2256716A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
IL128545A0 (en) 2000-01-31
NZ334897A (en) 2001-02-23
NO992769D0 (no) 1999-06-08
US5948780A (en) 1999-09-07
KR20000057444A (ko) 2000-09-15
AU5590698A (en) 1998-07-03
CA2263886A1 (en) 1998-06-18
MXPA99001974A (es) 2002-03-27
WO1998025597A3 (en) 2000-10-12
WO1998025597A2 (en) 1998-06-18
EP1028716A1 (en) 2000-08-23
AU741768B2 (en) 2001-12-06
NO992769L (no) 1999-08-09
JP2001526631A (ja) 2001-12-18
BR9714385A (pt) 2000-05-16

Similar Documents

Publication Publication Date Title
IL128545A0 (en) Method for treating and preventing heart failure and ventricular dilatation
EP1007152A4 (en) METHOD AND APPARATUS FOR TREATING CARDIAC ARRHYTHMIA
AU2531297A (en) Method and apparatus for rate-responsive cardiac pacing
SG32522A1 (en) Surface treatment method and system
EP1022945A4 (en) METHOD AND FORMULATION FOR THE TREATMENT OF VASCULAR DISEASES
AU3497395A (en) Irradiation catheter and method of use
EP0949941A4 (en) PROCESS FOR TREATING HEART FAILURE REQUIRING A DEFINED NEGATIVE INTRATHORACIC PRESSURE
AU1743195A (en) Method and apparatus for dual chamber cardiac pacing
EP0739644A4 (en) INTERFACE FOR A TRANSDERMAL IONTOPHORETIC DEVICE AND CORRECT MEDICINE
ZA977564B (en) Method of treatment
ZA991220B (en) Method of treating heart failure.
EP0783273A4 (en) IMPROVED LASER SYSTEM FOR MEDICAL USE, AND USE THEREOF
EP0673270A4 (en) IMPLANTABLE STIMULATION SYSTEM AND METHOD FOR STOPPING CARDIAC ARRHYTHMIAS.
GB9620412D0 (en) A method of treating a laminate
EP1018965A4 (en) METHOD FOR TREATING THE RISK FACTOR SYNDROME OF HUMAN CORONARY DISEASES
GB9605828D0 (en) Treatment method
ZA974978B (en) Formulation and method for treating congestive heart failure
IL125762A0 (en) Method for treating heart failure
ZA977867B (en) Method of treatment.
ZA973988B (en) Method of treatment
EP0763143A4 (en) METHOD FOR TREATING TITANIUM PARTS
GB9415902D0 (en) Method of treatment
GB9407335D0 (en) Method of treatment
GB9414652D0 (en) Method of treatment
AU4502193A (en) Method for the regenerative and preservative treatment of skins, specially bindings